Form 10-Q NEUROCRINE BIOSCIENCES For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Neurocrine Bio. (NBIX) PT Raised to $99 at Deutsche Bank
May 1, 2018 7:40 AM EDTDeutsche Bank raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $99.00 (from $97.00) while maintaining a Buy rating.
Analyst Andrew Peters commented, "Another solid quarter of commercial execution and continued pipeline advancement confirm our bullish outlook on Neurocrine, with continued success of the Ingrezza launch and further revenue... More
